title: The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
abstract: Nitrogen-containing bisphosphonates (N-BPs) are effective antiosteolytic agents in patients with multiple myeloma. Preclinical studies have also demonstrated that these agents have direct antitumor effects in vitro and can reduce tumor burden in a variety of animal models, although it is not clear whether such effects are caused by direct actions on tumor cells or by inhibition of bone resorption. N-BPs prevent bone destruction in myeloma by inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts, thereby preventing the prenylation of small GTPase signaling proteins. In this study, utilizing a plasmacytoma xenograft model without complicating skeletal lesions, treatment with zoledronic acid (ZOL) led to significant prolongation of survival in severe combined immunodeficiency mice inoculated with human INA-6 plasma cells. Following treatment with a clinically relevant dose of ZOL, histological analysis of INA-6 tumors from the peritoneal cavity revealed extensive areas of apoptosis associated with poly (ADP-ribose) polymerase cleavage. Furthermore, Western blot analysis of tumor homogenates demonstrated the accumulation of unprenylated Rap1A, indicative of the uptake of ZOL by nonskeletal tumors and inhibition of farnesyl pyrophosphate synthase. These studies provide, for the first time, clear evidence that N-BPs have direct antitumor effects in plasma cell tumors in vivo and this is executed by a molecular mechanism similar to that observed in osteoclasts.
authors.affiliation: Division of Stem Cell Transplantion and Immunotherapy, 2nd Department of Medicine, University of Kiel, Kiel, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Guenther
authors.forename: Sharon
authors.initials: S
authors.lastname: Gordon
authors.forename: Markus
authors.initials: M
authors.lastname: Tiemann
authors.forename: Renate
authors.initials: R
authors.lastname: Burger
authors.forename: Frank
authors.initials: F
authors.lastname: Bakker
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Green
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Baum
authors.forename: Anke J
authors.initials: AJ
authors.lastname: Roelofs
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rogers
authors.forename: Martin
authors.initials: M
authors.lastname: Gramatzki
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D016513:Mice, SCID; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D017368:Protein Prenylation; D014183:Transplantation, Heterologous; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid